pxs-5505
- Home
- pxs-5505
Fibrosis is the simple disease process that’s more important than you think
How does a company with a lead asset cancer drug also get into dermatology? What does blood cancer and keloid scars have in common? The answer is: fibrosis. Fibrosis is another word for scarring. It is the key in the process of healing where connective tissue replaces normal tissue to form scar tissue. It’s how
Read MorePublic
International expansion as more hospitals register for Pharmaxis’ cancer treatment trials
Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug, PXS-5505. The Company has launched new clinical trial sites in Taiwan in a planned expansion to boost patient recruitment. Designed for use in the treatment of myelofibrosis, a rare blood cancer with a poor prognosis,
Read MorePublic
Making their mark: Pharmaxis to continue clinical trials in revolutionary anti-skin scarring drug
In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with research into their anti-fibrotic drug pipeline. For those unfamiliar with their work, Pharmaxis is developing drugs based on their proprietary amine-oxidase technology. These drugs work by inhibiting an enzyme pathway that is key in the
Read MorePublic
First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed
Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir. Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,
Read MorePublic